跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MOVAPO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MOVAPO
Authorized
STANDARD
MOVAPO
paladin pharma inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
82756b72d56b371a
Company
paladin pharma inc.
Type
Standard
Approval Details
Approval Id
82756b72d56b371a
Drug Approval Canada Name
MOVAPO
Product Name
MOVAPO
Status
Cancelled Post Market
Status Date
2023-10-23
Original Market Date
2017-09-07
Din
02459132
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription
Ahfs
28:36.20.08
Atc Original
N04BC07 APOMORPHINE
Atc Name
n 04 bc 07
Aig Number
0158570001
Company Name
paladin pharma inc.
Company Address
100 Blvd Alexis-Nihon, Suite 600, Montreal, Quebec, Canada, H4M 2P2
Active Ingredients
APOMORPHINE HYDROCHLORIDE
10 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
82756b72d56b371a
Type
Standard
Back to Health Canada Approvals